• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ucb ADR (OP: UCBJY )

    96.57 -1.68 (-1.71%)
    Streaming Delayed Price Updated: 3:54 PM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,779
    Open 97.53
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 98.25
    Today's Range 96.02 - 97.57
    52wk Range 34.85 - 99.40
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
    UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48... 
    Via Benzinga
    Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
    Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets. 
    Via Benzinga

    Performance

    YTD
    +123.28%
    +123.28%
    1 Month
    +2.06%
    +2.06%
    3 Month
    +13.83%
    +13.83%
    6 Month
    +48.35%
    +48.35%
    1 Year
    +173.65%
    +173.65%

    More News

    Read More
    Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
    Via Talk Markets
    Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
    Via Benzinga
    Exposures Product Safety
    UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
    Via Benzinga
    Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
    Via Benzinga
    There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
    Via Benzinga
    Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
    Via Benzinga
    Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
    Via Benzinga
    FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
    Via Benzinga
    Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
    Via Benzinga
    The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
    Via Benzinga
    Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
    Via Benzinga
    The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
    Via Talk Markets
    The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
    Via Benzinga
    UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
    Via Benzinga
    ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
    Via Benzinga
    UCB Gets EU Approval For Bimekizumab In Psoriasis
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.